JP2018002640A - Pollen rupture inhibitor - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide pollen rupture inhibitors that can inhibit rupture of pollen attaching to or floating to effectively inhibit the release of allergen.SOLUTION: A pollen rupture inhibitor is characterized by containing at least two components selected from the group consisting of the following components (A), (B), (C), and (D): (A) glycyrrhizinic acid and/or salts thereof; (B) chondroitin sulfate and/or salts thereof; (C) chlorpheniramine and/or salts thereof; and(D) ε-aminocaproic acid and/or salts thereof.SELECTED DRAWING: None

Description

  The present invention relates to a pollen burst inhibitor that is applied to textiles, indoor spaces, and the like, suppresses pollen bursting, and suppresses release of allergen substances.

  Hay fever is a type of rhinitis that develops due to allergic reactions caused by foreign substances such as pollen. Hay fever continuously causes unpleasant symptoms such as itchy eyes, sneezing, runny nose, and stuffy nose for a long period of time, impairing daily life. The prevalence of hay fever is increasing every year and has become a social problem in recent years.

  The pathogenesis of hay fever has been elucidated by vigorous studies so far. Specifically, the pathogenesis of hay fever is as follows. First, when pollen of cedar or the like adheres to the mucous membrane of the eye or nose, the outer shell of the pollen ruptures, releasing an antigen protein (allergen substance) and entering the mucous membrane. When the antigenic protein enters the mucosa, specific IgE antibodies are produced and sensitization occurs by binding of the antibodies to receptors on mucosal mast cells. In this state, when the antigen protein is exposed again, the antibody-antigen reaction releases chemical mediators such as histamine from mast cells, and these substances bind to the receptor, causing allergic symptoms such as pruritus. .

  Conventionally, various methods for preventing hay fever have been reported. For example, Patent Document 1 reports that a hay fever prevention solution containing an amino acid metal salt can destroy pollen and render it harmless. However, although the technique of Patent Document 1 intends to detoxify the pollen by deliberately destroying it, it cannot prevent contact with the allergen substance released by the rupture of pollen and prevent hay fever. The effect is not enough.

  On the other hand, to prevent hay fever, it is effective to avoid contact with pollen, but it is difficult to completely avoid contact with pollen in daily life. For this reason, it is important to prevent the outer shell of the pollen from being ruptured even if it comes into contact with the pollen.

JP 2013-75879 A

  An object of the present invention is to provide a pollen rupture inhibitor that can suppress the rupture of adhering or floating pollen and can effectively suppress the release of allergen substances.

  The present inventor conducted intensive studies to solve the above-mentioned problems, and found that (A) glycyrrhizic acid and / or a salt thereof, (B) chondroitin sulfate and / or a salt thereof, (C) chlorpheniramine and / or It has been found that when at least two components of the salt, (D) ε-aminocaproic acid and / or salt thereof, are combined and contacted with pollen, rupture of pollen is extremely effectively suppressed. Moreover, it discovered that especially when the above-mentioned four components were combined, the burst of pollen was suppressed more effectively. The present invention has been completed by further studies based on these findings.

That is, this invention provides the invention of the aspect hung up below.
Item 1. A pollen burst inhibitor, comprising at least two components selected from the group consisting of the following components (A), (B), (C), and (D).
(A) Glycyrrhizic acid and / or salt thereof (B) Chondroitin sulfate and / or salt thereof (C) Chlorpheniramine and / or salt thereof (D) ε-aminocaproic acid and / or salt thereof Item 2. The pollen burst inhibitor according to Item 1, which is applied to a textile product or an indoor space.
Item 3. Item 3. The pollen burst inhibitor according to Item 1 or 2, comprising the component (A), the component (B), the component (C), and the component (D).
Item 4. (E) The pollen burst inhibitor according to any one of Items 1 to 3, further comprising a chelating agent.
Item 5. Item 5. The pollen rupture inhibitor according to any one of Items 1 to 4, which is a liquid agent.

  The pollen rupture inhibitor of the present invention can extremely effectively prevent the outer shell of pollen from rupturing. Therefore, it is possible to suppress the release of the allergen substance from the pollen, and thus suppress the onset of hay fever.

The pollen burst inhibitor of the present invention comprises at least two components selected from the group consisting of the following component (A), component (B), component (C), and component (D). .
(A) Glycyrrhizic acid and / or salt thereof (B) Chondroitin sulfate and / or salt thereof (C) Chlorpheniramine and / or salt thereof (D) ε-aminocaproic acid and / or salt thereof The inhibitor component will be described in detail.

(A) Glycyrrhizic acid and / or salt thereof Glycyrrhizic acid used in the present invention is 20β-carboxy-11-oxo-30-noroleana-12-en-3β-yl-2-O-β-D-glucopyranurono. It is a known compound also called syl-α-D-glucopyranoside uronic acid.

  The salt of glycyrrhizic acid is not particularly limited. Examples thereof include alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt; ammonium salt; arginine, lysine, histidine, ornithine and the like. Basic amino acid salts; amine salts such as monoethanolamine salts and diethanolamine salts. Among these, an alkali metal salt is preferable. These salts may be used individually by 1 type, and may be used in combination of 2 or more type.

  Further, glycyrrhizic acid and glycyrrhizic acid salts may be used alone or in combination of glycyrrhizic acid and glycyrrhizic acid salts. Among these, a salt of glycyrrhizic acid is preferable, an alkali metal salt of glycyrrhizic acid is more preferable, and dipotassium glycyrrhizinate is more preferable.

  Glycyrrhizic acid or a salt thereof is not particularly limited, and a chemically synthesized product may be used, or a product obtained by extraction or purification from a natural product-derived material may be used. Moreover, you may use the glycyrrhizic acid marketed as a reagent, or its salt.

  A method for producing glycyrrhizic acid or a salt thereof by extraction or purification from a natural product-derived material is not particularly limited, and examples thereof include a method for extraction or purification from a natural product-derived material by a known method. Examples of the natural product-derived material for extracting glycyrrhizic acid include licorice root.

  When the component (A) is used in the pollen burst inhibitor of the present invention, the content thereof is not particularly limited, but is, for example, 0.001 to 0.3% by weight, preferably 0.001 to 0.1% by weight. %, More preferably 0.005 to 0.05% by weight.

(B) Chondroitin sulfate and / or salt thereof Chondroitin sulfate used in the present invention is an acidic mucosic acid in which sulfuric acid is bound to a sugar chain having a disaccharide of N-acetyl-D-galactosamine and D-glucuronic acid as repeating structural units. It is a compound known as a polysaccharide.

  The salt of chondroitin sulfate is not particularly limited, but examples thereof include alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt; ammonium salt; arginine, lysine, histidine, ornithine and the like. Basic amino acid salts; amine salts such as monoethanolamine salts and diethanolamine salts. Among these, an alkali metal salt is preferable. These salts may be used individually by 1 type, and may be used in combination of 2 or more type.

  In addition, chondroitin sulfate and chondroitin sulfate salts may be used singly or in combination of chondroitin sulfate and chondroitin sulfate salts. Among these, a salt of chondroitin sulfate is preferable, an alkali metal salt of chondroitin sulfate is more preferable, and sodium chondroitin sulfate is more preferable.

  There is no limitation in particular as chondroitin sulfate or its salt, You may use what was chemically synthesized, and what was extracted or refine | purified from the material derived from a natural product may be used. Moreover, you may use the chondroitin sulfate marketed as a reagent, or its salt.

  The method for producing chondroitin sulfate or a salt thereof by extraction or purification from a natural product-derived material is not particularly limited, and examples thereof include a method for extraction and purification from a natural product-derived material by a known method. Examples of the material derived from a natural product for extracting chondroitin sulfate include mammals, fish cartilage such as salmon, ray, and shark. Among these, those derived from fish cartilage are preferred.

  When the component (B) is used in the pollen burst inhibitor of the present invention, the content thereof is not particularly limited, but is, for example, 0.005 to 5% by weight, preferably 0.005 to 3% by weight, and more preferably. Is 0.01 to 3% by weight.

(C) Chlorpheniramine and / or a salt thereof Chlorpheniramine used in the present invention is also called 3- (4-chlorophenyl) -N, N-dimethyl-3- (2-pyridinyl) propan-1-amine. It is a known compound.

Specific examples of the chlorpheniramine salt include organic acid salts such as maleate, hydrochloride and fumarate; inorganic acid salts; and various salts such as metal salts. Among these salts, organic acid salts are preferable, and maleates are more preferable. These chlorpheniramine salts may be used alone or in any combination of two or more.
Further, chlorpheniramine and a salt thereof may be in the form of a hydrate, and may be any of d-form, l-form, and dl-form.

  Further, each of chlorpheniramine and a salt of chlorpheniramine may be used alone or in combination with a salt of chlorpheniramine and chlorpheniramine. Among these, a salt of chlorpheniramine is preferable, an organic acid salt of chlorpheniramine is more preferable, and a maleate chlorpheniramine is more preferable.

  Chlorpheniramine or a salt thereof is not particularly limited, and may be chemically synthesized or extracted or purified from a natural product-derived material. Moreover, you may use the chlorpheniramine marketed as a reagent, or its salt.

  When the component (C) is used in the pollen burst inhibitor of the present invention, the content thereof is not particularly limited, but is, for example, 0.0001 to 0.1% by weight, preferably 0.0001 to 0.05% by weight. %, More preferably 0.0003 to 0.03% by weight.

(D) ε-aminocaproic acid and / or its salt The salt of ε-aminocaproic acid is not particularly limited. Specifically, alkali metal salts such as sodium salt and potassium salt; alkali such as calcium salt and magnesium salt Earth metal salts; inorganic acid salts such as hydrochlorides and sulfates. These salts of ε-aminocaproic acid may be used alone or in combination of two or more.

  Further, ε-aminocaproic acid and a salt of ε-aminocaproic acid may be used alone, respectively, or a combination of ε-aminocaproic acid and ε-aminocaproic acid may be used. Among these, ε-aminocaproic acid is preferable.

  There is no limitation in particular as (epsilon) -aminocaproic acid or its salt, Chemically synthesized thing may be used, and (epsilon) -aminocaproic acid or its salt marketed as a reagent may be used.

  In the case of using the component (D) in the pollen burst inhibitor of the present invention, the content thereof is not particularly limited, but is, for example, 0.001 to 1% by weight, preferably 0.01 to 1% by weight, and more preferably. Is 0.01 to 0.5% by weight.

  The pollen rupture inhibitor of the present invention contains at least two components among the above-mentioned components (A) to (D), but the combination of the components from the viewpoint of further improving the pollen rupture inhibitory effect. As an embodiment, preferably an embodiment containing at least (A) component and (B) component, or an embodiment containing at least (A) component and (C) component, more preferably at least (A) component and (B) component The aspect containing is mentioned.

  Furthermore, from the viewpoint of further improving the effect of suppressing pollen rupture, the combination of the aforementioned components (A) to (D) is more preferably (A) component, (B) component, (C) component, And at least three components selected from the group consisting of component (D), particularly preferably the component (A), component (B), component (C), and component (D).

  When the pollen rupture inhibitor of the present invention contains at least three components selected from the group consisting of the component (A), component (B), component (C), and component (D), The combination of the components is preferably a combination of the component (A), the component (B) and the component (C), or a combination of the component (A), the component (B) and the component (D), more preferably. The combination of (A) component, (B) component, and (C) component is mentioned.

  When the pollen burst inhibitor of the present invention contains, for example, the component (A), the component (B), and the component (C), the ratio thereof is not particularly limited, but is 1 part by weight of the component (A). The component (B) is preferably 0.1 to 10 parts by weight, the component (C) is 0.02 to 3 parts by weight, more preferably the component (B) is 0.2 to 6 parts by weight, (C) The component is 0.05 to 1 part by weight.

  Moreover, when the pollen burst inhibitor of this invention contains (A) component, (B) component, and (D) component, for example, although it does not specifically limit about (A) component 1 weight part The component (B) is preferably 0.1 to 10 parts by weight, the component (D) is 2 to 20 parts by weight, more preferably the component (B) is 0.2 to 6 parts by weight, (D) The component is 2 to 10 parts by weight.

  Moreover, when the pollen burst inhibitor of this invention contains (A) component, (B) component, (C) component, and (D) component, for example, although it does not specifically limit, (A ) The component (B) is preferably 0.1 to 10 parts by weight, the component (C) is 0.02 to 3 parts by weight, and the component (D) is 2 to 20 parts by weight relative to 1 part by weight of the component. The component (B) is preferably 0.2 to 6 parts by weight, the component (C) is 0.05 to 1 part by weight, and the component (D) is 2 to 10 parts by weight.

(E) Chelating Agent The pollen burst inhibitor of the present invention may further contain a chelating agent (hereinafter sometimes referred to as (E) component). By further containing a chelating agent, the pollen burst inhibiting effect can be further improved.

  The type of chelating agent used in the present invention is not particularly limited. For example, ethylenediaminetetraacetic acid (edetic acid), nitrilotriacetic acid, hydroxyethyliminodiacetic acid, dihydroxyethylglycine, hydroxyethylenediaminetriacetic acid, diethylenetriaminepentaacetic acid. , Triethylenetetramine hexaacetic acid, tartaric acid, metasilicic acid, citric acid, orthosilicic acid, glucuronic acid, and salts thereof. Specific examples of salts of these compounds include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts.

  These chelating agents may be used individually by 1 type, and may be used in combination of 2 or more type.

  Among these chelating agents, edetic acid and salts thereof are preferable, alkali metal salts of edetic acid are more preferable, and sodium edetate is more preferable.

  When the pollen burst inhibitor of the present invention contains the component (E), the content is not particularly limited, but is, for example, 0.0001 to 1% by weight, preferably 0.001 to 1% by weight, and more preferably. Is 0.001 to 0.3% by weight.

(F) Surfactant The pollen rupture inhibitor of the present invention may contain a surfactant (hereinafter also referred to as (F) component) as necessary.

  The type of surfactant used in the present invention is not particularly limited, and any of nonionic surfactants, anionic surfactants, cationic surfactants, and amphoteric surfactants may be used. Preferably, a nonionic surfactant is used.

  Specific examples of the surfactant include POE (10-50 mol) phytosterol ether, POE (10-50 mol) dihydrocholesterol ether, POE (10-50 mol) 2-octyldodecyl ether, POE (10-50 mol). Mol) decyltetradecyl ether, POE (10-50 mol) oleyl ether, POE (2-50 mol) cetyl ether, POE (5-50 mol) behenyl ether, POE (5-30 mol) polyoxypropylene (5-5 mol) 30 mol) Polyoxyethylene alkyl ethers such as 2-decyltetradecyl ether, POE (10 to 50 mol) polyoxypropylene (2 to 30 mol) cetyl ether, phosphoric acid / phosphate thereof (POE cetyl ether phosphoric acid) Sodium), POE (20-60 mol) sol Polyoxyethylene sorbitan fatty acid esters such as tan monooleate, POE (20-60 mol) sorbitan monostearate, POE (10-60 mol) sorbitan monoisostearate, POE (10-80 mol) glyceryl monoisostearate , POE (10-30 mol) glyceryl monostearate, POE (20-100 mol) polyoxypropylene modified silicone, POE alkyl modified silicone, polyethylene glycol monolaurate, polyethylene glycol monopalmitate, polyethylene glycol monostearate, Polyethylene glycol dilaurate, polyethylene glycol dipalmitate, polyethylene glycol distearate, polyethylene glycol dioleate, polyglycine diricinoleate Tylene glycol, polyoxyethylene hydrogenated castor oil (5 to 100), glycerin fatty acid ester (such as glyceryl monostearate), hydrogenated soybean phospholipid, hydrogenated lanolin alcohol, fatty acid polyglyceryl (such as polyglyceryl stearate), amino acids and fatty acids Examples include amide bonds (such as sodium stearoyl glutamate).

These surfactants may be used individually by 1 type, and may be used in combination of 2 or more type.
Among these surfactants, preferably nonionic surfactants, more preferably polyoxyethylene sorbitan fatty acid esters, more preferably POE (20 to 60 mol) sorbitan monooleate, particularly preferably POE (20 mol) sorbitan. Monooleate (ie polysorbate 80).

  When the pollen burst inhibitor of the present invention contains the component (F), the content thereof is not particularly limited, but is, for example, 0.0001 to 3% by weight, preferably 0.0001 to 1% by weight, and more preferably. 0.001 to 0.1% by weight.

(G) Terpenoid The pollen rupture inhibitor of the present invention may further contain a terpenoid (hereinafter also referred to as (G) component). Terpenoids are also called isoprenoids or terpenes, and are usually compounds in which a plurality of isoprene units (5 carbon atoms) are bonded. Terpenoids are monoterpenes (2 isoprene units), sesquiterpenes (3 isoprene units), diterpenes (4 isoprene units), triterpenes (6 isoprene units) depending on the number of isoprene units contained. And so on. Any of these terpenoid compounds may be used in the pollen burst inhibitor of the present invention.

  Specific examples of monoterpenes include alcohol-based monoterpenes such as menthol, thymol, geraniol, linalool, borneol, cineol, and terpineol; aldehyde-based monoterpenes such as citral, citronellal, perylaldehyde, and safranal; camphor, menthone, and carbo Mentones such as menthone and ketones such as monoterpenes. As sesquiterpenes, specifically, camazulene, santalen, patchulene, cedrol, cedrenol, farnesol, eugenol, α-bisabolol, β-caryophyllene alcohol, sclareol, geranyl linalool, isophitol, nerolidol, globrol, guaioles, α-Santalol, Catolol, Farnesal, Germacron, Ciperon, Zerumbon, Betivon and the like can be mentioned. Specific examples of diterpenes include retinal and the like. These terpenoids may be any of d-form, l-form and dl-form when optical isomers are present.

  These terpenoids may be used individually by 1 type, and may be used in combination of 2 or more type.

  Among these terpenoid compounds, monoterpenes are preferable, alcohol monoterpenes are more preferable, and menthol and borneol are particularly preferable.

  These terpenoids may be used in the state of an essential oil containing terpenoids. The essential oil containing terpene can be appropriately selected from known ones, and examples of the essential oil containing menthol include peppermint oil, peppermint oil, spearmint oil, and the like.

  When the pollen burst inhibitor of the present invention contains the component (G), the content is not particularly limited, but is, for example, 0.0001 to 1% by weight, preferably 0.0001 to 0.5% by weight, More preferably, 0.001-0.05 weight% is mentioned.

pH
The pH of the pollen rupture inhibitor of the present invention is not particularly limited as long as it has a pollen rupture inhibitory action, but is generally 4 to 7.5, preferably 4 to 7, and more preferably 4 to 6.5. . The method for adjusting the pH of the pollen burst inhibitor is not particularly limited, and can be adjusted by including a known pH adjuster. Although it does not specifically limit as a pH adjuster, For example, acids, such as hydrochloric acid, boric acid, aminoethylsulfonic acid, a citric acid, an acetic acid, phosphoric acid, tartaric acid; Sodium hydroxide, potassium hydroxide, calcium hydroxide, hydroxylation Examples include alkalis such as magnesium and sodium hydrogen carbonate.

Other components The pollen burst inhibitor of the present invention contains other components as necessary within the range not affecting the effects of the present invention, in addition to the components (A) to (E) described above. Also good. Other components are not particularly limited, and may be appropriately selected according to the dosage form and product form of the pollen rupture inhibitor of the present invention, for example, buffer, thickener, stabilizer, preservative, Antibacterial agents, bactericides, antioxidants, fillers, deodorants, buffers, ultraviolet absorbers, fragrances, dyes, enzymes, salts, sugars, sugar alcohols, amino acids, terpenoids and the like can be mentioned. These components may be used individually by 1 type, and may be used in combination of 2 or more type.

  The pollen burst inhibitor of the present invention may contain a solvent for application to an object on which pollen is floating or adhering in a state where the aforementioned components are dissolved. The solvent is not particularly limited as long as it can dissolve the above-mentioned components, and can be appropriately selected from conventionally known ones. For example, water; methanol, ethanol, propanol, isopropanol, butanol , Isobutanol, sec-butanol, t-butanol, pentanol, hexanol, cyclohexanol, benzyl alcohol and other alcohols; ethylene glycol, diethylene glycol, triethylene glycol, polyethylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, butylene Polyhydric alcohols such as glycol, hexanediol, pentanediol, glycerin, hexanetriol, thiodiglycol; ethylene glycol monomethyl ether, Tylene glycol monoethyl ether, ethylene glycol monobutyl ether, diethylene glycol monomethyl ether, diethylene glycol monobutyl ether, propylene glycol monomethyl ether, propylene glycol monobutyl ether, dipropylene glycol monomethyl ether, triethylene glycol monomethyl ether, ethylene glycol diacetate, ethylene glycol monomethyl ether Glycol derivatives such as acetate triethylene glycol monoethyl ether and ethylene glycol monophenyl ether; ethanolamine, diethanolamine, triethanolamine, N-methyldiethanolamine, N-ethyldiethanolamine, morpholine, N-ethylmorpholine, ethylenedia Emissions, diethylenetriamine, triethylenetetramine, polyethyleneimine, amines such as tetramethyl propylene diamine; and the like.

  These solvents may be used individually by 1 type, and may be used in combination of 2 or more type.

  Among these solvents, water and a mixed solution of water and an organic solvent are preferable, and water is more preferable.

Production Method The pollen burst inhibitor of the present invention comprises at least two components selected from the group consisting of the above-mentioned component (A), component (B), component (C), and component (D), and if necessary. The other components added can be prepared by adding to the solvent and mixing.

Form The form of the pollen rupture inhibitor of the present invention is not particularly limited, and examples thereof include known product forms such as a liquid agent, an aerosol agent, a solid agent, and a gel agent. In addition, depending on the product form, the pollen rupture inhibitor may appropriately contain components generally contained in the product form. Especially, as a form of a pollen rupture inhibitor, a liquid agent is preferable in terms of easy handling.

  The pollen rupture inhibitor of the present invention can be used, for example, as a spray agent, an air spray agent, etc. by accommodating the pollen rupture inhibitor of the present invention in an aerosol dispenser container. In addition, for example, a fiber product for preventing hay fever can be obtained by applying or impregnating the pollen burst inhibitor of the present invention to a fiber product. Specific examples of the fiber product for preventing hay fever include, for example, a sheet material for wiping the body such as the face and body, windows, floors, walls, etc. to which pollen can adhere. In addition, the pollen rupture inhibitor of the present invention can be used as a detergent that can clean an object while suppressing rupture of pollen attached to the object, for example, by using it together with a cleaning component such as a surfactant. it can.

Method of Use The pollen rupture inhibitor of the present invention is applied to an object for which suppression of pollen rupture is required. The target is not particularly limited as long as it is a space in which pollen may or may not float, or pollen may or may adhere thereto. For example, a space in a room or a car; a window; ; Walls; floors; textile products such as curtains, carpets, futons, clothes, masks; bodies (mucous membranes, skin); accessories such as watches, necklaces, bracelets, rings; furniture; books and the like.

  The method for using the pollen rupture inhibitor of the present invention is not particularly limited, and a known method may be appropriately selected according to the form of the pollen rupture inhibitor, the type of an appropriate target, and the like. For example, the method of apply | coating the spray pollutant suppression agent of this invention to an application object, spraying, or washing away an application object etc. are mentioned.

  The amount of the pollen rupture inhibitor used in the present invention is not particularly limited as long as the pollen rupture inhibitory effect is exhibited, and may be applied in an appropriate amount to the subject.

  EXAMPLES Next, although an Example demonstrates this invention further in detail, this invention is not limited at all by these examples.

<Experimental example 1>
Examples 1-6, Comparative Examples 1-3
Each component was weighed and dissolved in purified water so as to have the composition shown in Table 1, to prepare a liquid. The pollen rupture rate of the obtained pollen rupture inhibitor and the amount of pollen antigen protein eluted were evaluated by the following methods.

(Pollen burst rate)
Sugi pollen (manufactured by Wako Pure Chemical Industries, Ltd.) was turbid in the liquid obtained as described above so that the pollen concentration was 10 mg / ml, and incubated at 37 ° C. After 5 minutes, 10 μl of the turbid solution was dropped on a slide glass and covered with a cover glass, and 200 pollens were counted under an optical microscope (magnification 100 times). The number of pollen ruptured out of 200 pollen was counted, and the pollen rupture rate was calculated by the following formula.

(Quantification of the amount of antigen protein released)
For the liquid preparations of Examples 1 and 2 and Comparative Example 3, the amount of released antigen protein (Cry j 1 and Cry j 2) was quantified according to the following method. Sugi pollen (manufactured by Wako Pure Chemical Industries, Ltd.) was turbid in each solution so as to be 10 mg / ml, and incubated at 37 ° C. After 5 minutes, it was quickly cooled with ice water and centrifuged at 11,000 g for 3 minutes at 4 ° C. The supernatant was collected and centrifuged again. Thereafter, the supernatant (recovered solution) was collected, and Cry j 1 was quantified by the sandwich method using ELISA kit (manufactured by Special Immunity Research Institute). Cry j 2 was quantified under the same conditions as Cry j 1 except that cedar pollen (manufactured by Wako Pure Chemical Industries, Ltd.) was turbid in each solution so as to be 200 mg / ml.

  The results are shown in Table 1. According to Table 1, a solution containing at least three components of dipotassium glycyrrhizinate, sodium chondroitin sulfate, chlorpheniramine maleate, and ε-aminocaproic acid contains only one or none of these components. The pollen rupture rate was low, and it was shown to have a pollen rupture inhibitory effect. In particular, when at least dipotassium glycyrrhizinate and sodium chondroitin sulfate were included (Examples 4 and 5), it was shown that the effect of suppressing pollen rupture was significantly increased.

  In addition, when all four components of dipotassium glycyrrhizinate, chondroitin sulfate sodium salt, chlorpheniramine maleate, and ε-aminocaproic acid are included, the pollen rupture rate is less than about 15%, and the pollen rupture suppression is extremely excellent. It also became clear that it has an effect | action (Example 1, 6).

<Experimental example 2>
Example 7
A pollen burst inhibitor was prepared so as to have the same composition as in Example 1 except that the pH was adjusted to 6.0, and the pollen burst rate and antigen protein elution amount were evaluated by the same method as in Experimental Example 1 above. did. The results are shown in Table 2 together with Example 1.

  From Table 2, in the liquid agent containing dipotassium glycyrrhizinate, chondroitin sulfate ester sodium, chlorpheniramine maleate, and ε-aminocaproic acid, the pH 6.0 is compared to the pH 7.1, It was shown that the effect of suppressing pollen rupture was significantly improved.

Claims (5)

A pollen burst inhibitor, comprising at least two components selected from the group consisting of the following components (A), (B), (C), and (D).
(A) Glycyrrhizic acid and / or salt thereof (B) Chondroitin sulfate and / or salt thereof (C) Chlorpheniramine and / or salt thereof (D) ε-aminocaproic acid and / or salt thereof   The pollen burst inhibitor according to claim 1, which is applied to a textile product or an indoor space.   The pollen burst inhibitor of Claim 1 or 2 containing the said (A) component, (B) component, (C) component, and (D) component.   (E) The pollen burst inhibitor according to any one of claims 1 to 3, further comprising a chelating agent.   The pollen burst inhibitor according to any one of claims 1 to 4, which is a liquid agent.